ArticleIET systems biology
Identification of Mitochondria- and Macrophage Activation-Related Hub Genes in Sarcopenia.
Article in IET systems biology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
To explore the hub genes and pathways associated with sarcopenia progression from the perspective of mitochondrial dysfunction and macrophage activation. The GEO datasets GSE8479, GSE1428 and GSE136344 were obtained from the GEO database. Mitochondria-related genes (MRGs) and macrophage activation-related genes (MARGs) were identified. Functional enrichment analyses, PPI analysis, diagnostic model construction, molecular subtyping and ssGSEA-based immune enrichment analysis were performed. Key genes were further validated by RT-qPCR. A total of 62 mitochondria- and macrophage activation-related differentially expressed genes (M&MARDEGs) were identified. Nine key genes (IGF1, FTL, MAPK8, MAPK9, TF, CREB1, FAS, VEGFA and NFKB1) were retained in the final diagnostic model. Immune enrichment analysis suggested distinct immune-related transcriptional characteristics among different risk groups and molecular subtypes. RT-qPCR validation demonstrated that IGF1, FAS and MAPK9 were significantly downregulated, whereas FTL, TF, CREB1 and NFKB1 were significantly upregulated in the sarcopenia model group. MAPK8 and VEGFA showed decreasing trends without statistical significance. Integrated transcriptomic analysis identified key genes potentially associated with sarcopenia through the intersection of mitochondrial dysfunction and macrophage activation. These findings provide insights into the molecular characteristics of sarcopenia and may offer candidate targets for future mechanistic and translational studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.